Lin MC, Chang YY, Lee Y, Wang LJ. Tardive sensory syndrome related to lurasidone: A case report. World J Psychiatry 2023; 13(3): 126-130 [PMID: 37033893 DOI: 10.5498/wjp.v13.i3.126]
Corresponding Author of This Article
Yu Lee, MD, MS, Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, No. 123, Dapi Road, Niaosung District, Kaohsiung 83301, Taiwan. lyu722@cgmh.org.tw
Research Domain of This Article
Psychiatry
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Mar 19, 2023; 13(3): 126-130 Published online Mar 19, 2023. doi: 10.5498/wjp.v13.i3.126
Tardive sensory syndrome related to lurasidone: A case report
Mei-Chun Lin, Yung-Yee Chang, Yu Lee, Liang-Jen Wang
Mei-Chun Lin, Yu Lee, Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, Kaohsiung 83301, Taiwan
Yung-Yee Chang, Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, Kaohsiung 83301, Taiwan
Liang-Jen Wang, Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan
Author contributions: Lin MC participated in this case report’s design and coordination, was involved in data acquisition, and drafted the manuscript; Chang YY participated in both its design and coordination; Lee Y and Wang LJ are co-corresponding authors, they conceived the idea of this case report and its design, and were involved in revising and finalizing the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Lee, MD, MS, Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine Kaohsiung, No. 123, Dapi Road, Niaosung District, Kaohsiung 83301, Taiwan. lyu722@cgmh.org.tw
Received: October 12, 2022 Peer-review started: October 12, 2022 First decision: October 30, 2022 Revised: November 17, 2022 Accepted: February 14, 2023 Article in press: February 14, 2023 Published online: March 19, 2023
Abstract
BACKGROUND
Tardive sensory syndrome (TSS) is a subtype of tardive syndrome (TS), and its etiology is still uncertain. Lurasidone is an atypical antipsychotic that has high affinity for dopamine D2- and serotonergic 5HT2A- and 5-HT7-receptors.
CASE SUMMARY
A 52-year-old woman, previously diagnosed with schizophrenia, and with no history of movement disorders and no sensory paresthesia, had taken lurasidone, initiate dose 40 mg daily then up titration to 120 mg daily, since March 2021, and developed mandibular sensory (pain) paresthesia after 3 mo of administration. After switching from lurasidone to quetiapine, she reported obvious impr-ovement in her mandibular pain.
CONCLUSION
It is noteworthy that TSS is a rare subtype of TS, and lurasidone, an atypical antipsychotic, usually has a lower risk of causing TS. In light of the temporal relationship, it is therefore concluded that use of lurasidone might have caused TSS in this patient. We reported this rare case as a reminder that clinicians should adopt a cautious approach when prescribing atypical antipsychotics, so as to prevent TS.
Core Tip: Tardive sensory syndrome is a subtype of tardive syndrome (TS), and its etiology is still uncertain. Lurasidone is an atypical antipsychotic that has high affinity for dopamine D2- and serotonergic 5HT2A- and 5-HT7-receptors. We reported a 52-year-old woman with schizophrenia developed mandibular sensory (pain) paresthesia after 3 mo of administration of lurasidone. This case report reminds clinicians should adopt a cautious approach when prescribing atypical antipsychotics, so as to prevent TS.
